Pahr Therapeutics is a clinical-stage company focused on developing novel mechanisms to treat pulmonary arterial hypertension (PAH). The company was co-founded by researchers at the National Cerebral and Cardiovascular Center (NCVC) in Osaka, Japan, including Drs. Yoshikazu Nakaoka, Makoto Okazawa, and Ryotaro Asano. Pahr was incubated at Raven, the incubator of RA Capital Management, and is led by Neil Buckley, a Venture Partner at Raven. Dr. Nakaoka’s research in the molecular pathophysiology of PAH has guided the company’s novel approaches. The company plans to advance into clinical studies early next year and will use the financing proceeds to develop its therapies. Contact information and the company website are provided in the announcement.

Total raised

$14M

Funding rounds

1

Latest round

Seed

Latest activity

Jul 2025